key: cord-0951613-vqlujgk1 authors: Lalaoui, Rym; Bakour, Sofiane; Raoult, Didier; Verger, Pierre; Sokhna, Cheikh; Devaux, Christian; Pradines, Bruno; Rolain, Jean-Marc title: What could explain the late emergence of COVID-19 in Africa? date: 2020-09-22 journal: New Microbes New Infect DOI: 10.1016/j.nmni.2020.100760 sha: 7b3c440a9abcf522bd0b300c7de47dab049abed2 doc_id: 951613 cord_uid: vqlujgk1 At the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despite drastic containment measures, this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pandemic is ongoing with particular hotspot in Southern Europe and America in Spring 2020. Many studies predicted a similar epidemic in Africa as that currently seen in Europe and the United States of America. However, reported data do not confirm these predictions. Several hypotheses that could explain the later emergence and spread of COVID-19 pandemic in African countries are being discussed, including the lack of health care infrastructure capable of clinically detecting and confirming COVID-19 cases, the implementation of social distancing and hygiene, international air traffic flows, the climate, the relatively young and rural population, the genetic polymorphism of the ACE2 receptor, cross-immunity and the use of antimalarial drugs. vitro inhibition of SARS-CoV-2 replication that ranged from 30 to 70% [119] . The 298 combination mefloquine-artesunate was found to be the most effective in vitro against SARS-299 CoV-2. A patient treated by ACT for uncomplicated malaria could be protected from SARS- [53] https://www.afro.who.int/news/senegal-reports-first-covid-19-case (Accessed 13 513 August 2020). [54] https://www.ghanabusinessnews.com/2020/03/12/ghana-confirms-first-covid-19-cases/ 515 (Accessed 13 August 2020). [55] https://www.health.go.ke/first-case-of-coronavirus-disease-confirmed-in-kenya/ 517 (Accessed 13 August 2020). [56] https://www.afro.who.int/news/first-case-covid-19-confirmed-ethiopia (Accessed 13 519 August 2020). [70] Auler AC, Cássaro FAM, da Silva VO, Pires LF. Evidence that high temperatures and Influence 615 of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired 616 glucose tolerance in healthy subjects Genetic 619 variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population 620 cohorts from multiple continents Human neutralizing antibodies 623 elicited by SARS-CoV-2 infection Analysing of a SARS-CoV-2 infected individual reveals development of potent 627 neutralizing antibodies with limites somatic mutation Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging 631 Respiratory Coronaviruses Potent cross-reactive 634 neutralization of SARS coronavirus isolates by human monoclonal antibodies Cross-reactive 640 antibody response between SARS-CoV-2 and SARS-CoV infections Lack of 643 antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections Lack of cross-646 neutralization by SARS patient sera towards SARS-CoV-2 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 650 disease and unexposed individuals Selective and cross-653 reactive SARS-CoV-2 T cell epitopes in unexposed humans reactive T cells in healthy donors and patients with COVID-19 SARS-CoV-659 2-specific T cell immunity in cases of COVID-19 and SARS Phenotype and kinetic of SARS-CoV-2-specific T cells in COVID-19 patients with 666 acute respiratory distress syndrome Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Hospitalization rates and characteristis of children aged <18 years hospitalized with 673 laboratory-confirmed COVID-19 -COVID-NET, 14 states Transmission dynamis of SARS-CoV-2 within families with children in Greece: a 677 study of 23 clusters COVID-19 virus 679 and children: What do we know? Comparison of automated microarray detection with real-time PCR assays for detection 683 of respiratory viruses in specimens obtained from children Common human coronavirus 689 seem at least as severe as influenza in patients hospitalized with acute respiratory 690 infection: results from 8-year hospital-based surveillance in Quebec BCG caccine protection from severe 693 coronavirus disease 2019 (COVID-19) Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread 697 and mortality Could BCG vaccination induce 699 protective trained immunity for SARS-CoV-2? Strong homology between 702 SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid 703 diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 704 immunity via BCG vaccine Cross-protection 707 induced by Encephalitis vaccines against COVID-19 might be a reason for relatively 708 lower mortality rate in some countries Global Spread of coronavirus disease 2019 and malaria Is the new coronavirus (COVID-19) pandemic halted by 714 malaria epidemics? Plasmodium falciparum infection may protect a 717 population from SARS-CoV-2 infection Countries which primarily use antimalarial drugs as COVID-19 treatment 723 see slower dynamic of daily deaths Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate Anti-SARS-CoV-2 potentials of 729 artemisinins in vitro Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors 732 for inhibition of SARS-coV replication in BALB/c mice The authors thank CookieTrad for proofreading the text. 328